Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24828263 | 0.84 | TSHR (0.43) | MAP3K5TSHRKDM4EMAPT | |
| SCHEMBL20098543 | 0.84 | LMNA (0.51) | LMNATP53TSHRELANECSNK1D | |
| SCHEMBL22897231 | 0.84 | LMNA (0.45) | LMNATP53TSHRELANECSNK1D | |
| SCHEMBL21723853 | 0.83 | MAP3K5 (0.45) | MAP3K5L3MBTL1POLB | |
| SCHEMBL30871860 | 0.82 | LMNA (0.44) | LMNATP53TSHRELANEL3MBTL1 | |
| SCHEMBL21724351 | 0.81 | LMNA (0.43) | LMNAMAP3K5TP53TSHRELANE | |
| SCHEMBL21570236 | 0.80 | TSHR (0.39) | LMNATSHRELANECSNK1DPOLB | |
| SCHEMBL21724143 | 0.80 | MAP3K5 (0.45) | MAP3K5TSHRPOLBKDM4EMAPT | |
| SCHEMBL21724093 | 0.80 | TEAD2 (0.41) | TSHRCSNK1DKDM4EMAPTMAPK1 | |
| SCHEMBL31352155 | 0.79 | LMNA (0.58) | LMNAELANECSNK1DL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999715-B2 | ASK1 inhibiting agents | BIOGEN MA INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-3837251-B1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-3837251-B1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20210317103-A1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210317103-A1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC. | 2021-10-14 | — | — | US | disclosed |
| CN-113227070-A | ASK1 inhibitors | 比奥根MA公司 | 2021-08-06 | — | — | CN | disclosed |
| EP-3837251-A1 | ASK1 INHIBITING AGENTS | Biogen MA Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020036949-A1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020036949-A1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317103-A1 | ASK1 INHIBITING AGENTS | MAP3K1, MAP3K6, MAP3K10 | LMNA 2137/4885MAP3K5 10/4885TP53 103/4885 |
| US-11999715-B2 | ASK1 inhibiting agents | MAP3K1, MAP3K6, MAP3K10 | LMNA 2137/4885MAP3K5 10/4885TP53 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.